<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30197363</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>30</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>30</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1998-4138</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>14</Volume>                    <Issue>5</Issue>                    <PubDate>                        <MedlineDate>2018 Jul-Sep</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Journal of cancer research and therapeutics</Title>                <ISOAbbreviation>J Cancer Res Ther</ISOAbbreviation>            </Journal>            <ArticleTitle>Lobular breast cancer metastasis to uterus during adjuvant tamoxifen treatment: A case report and review of the literature.</ArticleTitle>            <Pagination>                <MedlinePgn>1135-1137</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4103/0973-1482.187235</ELocationID>            <Abstract>                <AbstractText>Tamoxifen plays a critical role in the treatment of hormone receptor-positive breast cancer. Despite these great benefits against breast cancer, tamoxifen increases the risk of endometrial pathologies such as endometrial hyperplasia, polyp, and neoplasms because of agonistic effect on endometrial tissues. Therefore, gynecologic follow-up should be carried out during tamoxifen treatment. Uterine tumors are frequently detected as the result of presentation with abnormal uterine bleeding. In addition, genital tract's metastases from distant primary tumors can present with abnormal uterine bleeding. Therefore, it is important to determine whether the uterine mass is metastatic or primary because different treatment modalities are used for them. In this context, breast carcinomas are the most frequent metastatic tumors, particularly invasive lobular carcinoma. Here, we report an invasive lobular carcinoma case that presented with abnormal uterine bleeding while receiving tamoxifen therapy and has metastasize in the uterus.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Aytekin</LastName>                    <ForeName>Aydin</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bilgetekin</LastName>                    <ForeName>Irem</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ciltas</LastName>                    <ForeName>Aydin</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ogut</LastName>                    <ForeName>Betul</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Coskun</LastName>                    <ForeName>Ugur</ForeName>                    <Initials>U</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Benekli</LastName>                    <ForeName>Mustafa</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D002363">Case Reports</PublicationType>                <PublicationType UI="D016422">Letter</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>India</Country>            <MedlineTA>J Cancer Res Ther</MedlineTA>            <NlmUniqueID>101249598</NlmUniqueID>            <ISSNLinking>1998-4138</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>094ZI81Y45</RegistryNumber>                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018275" MajorTopicYN="N">Carcinoma, Lobular</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014594" MajorTopicYN="N">Uterine Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014599" MajorTopicYN="N">Uterus</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Adjuvant treatment</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">lobular carcinoma</Keyword>            <Keyword MajorTopicYN="N">tamoxifen</Keyword>            <Keyword MajorTopicYN="N">uterine metastasis</Keyword>        </KeywordList>        <CoiStatement>There are no conflicts of interest</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30197363</ArticleId>            <ArticleId IdType="pii">JCanResTher_2018_14_5_1135_187235</ArticleId>            <ArticleId IdType="doi">10.4103/0973-1482.187235</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>